PPT-Optimizing Nursing Management of Patients Receiving Novel Therapies for Advanced NSCLC

Beth Eaby Sandy MSN CRNP OCN Nurse Practitioner Abramson Cancer Center of the University of Pennsylvania Disclosure of Conflicts of Interest Beth Eaby Sandy MSN CRNP O CN . No 41021 ISBN 9781771160230 Copyright 57513 College of Nurses of Ontario 2014 Commercial or forprofit redistribution of this document in part or in whole is prohibited except with the written consent of CNO This document may be reproduced in part or Nathan Pennell, M.D., Ph.D.. September 6, 2014. Objectives. Discuss the role of chemotherapy in molecularly defined populations. Discuss the addition of chemo and/or bevacizumab (Avastin) to targeted therapy. Renato G. Martins, MD, MPH. Medical Director, Thoracic/Head and Neck; General Oncology and Hematology. Seattle Cancer Care Alliance. July 28, 2015. 11:30 am – 12:30 pm, EST. ICLIO e-Course 02. Objectives. Jared Weiss, MD . Assistant . Professor of Medicine . Division . of Hematology and Oncology . University . of North Carolina School of Medicine . Attending Physician. UNC . Lineberger. Comprehensive Cancer . NSG . 404: Fundamentals . of . Evidence-Based . Practice. . Key Findings. Key Practices . Recommended. References. . Significance Statement. . Key Methodology. For patients in palliative and hospice care, complementary therapy compared to pharmacological measures alone may provide better symptom . Medical Director, Heart Failure and Cardiac Transplant Program. University of Pennsylvania. What Are Advanced Therapies?. Heart Transplant. Ventricular Assisted Devices (VAD). Mechanical Circulatory Support (MCS). The Coming Paradigm Shift. Faculty. Suresh S. Ramalingam, MD. Professor of Hematology/Oncology . Director, Lung . Cancer Program . Winship Cancer Institute. Emory University. Atlanta, . Georgia. Program Goals. Dr Tan . Jiunn. Liang. Clinical Specialist (Respiratory Medicine). Department of Medicine. Universiti. Malaya Medical Centre. Disclaimer. This program is provided as a service to the medical profession and represents the opinions of the speakers, not necessarily those of Merck or MSD or its affiliates. actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Disclosures for . Dr. Langer. Advisory Committee. Abbott Laboratories, AstraZeneca Pharmaceuticals LP, . Interview with Shirish M . Gadgeel. , MD . January 14, 2020. Case 1: 72-year-old woman enrolled on KEYNOTE-021. 2014: 72-year-old female patient with chest pain, cough and dyspnea is diagnosed with Stage IV squamous cell carcinoma. Abramson Cancer Center . University of Pennsylvania. Philadelphia, Pennsylvania. Keeping Up in NSCLC: Actionable Biomarkers and Their Impact on Treatment. Rasheda Persinger, MSN, AGNP-C, AOCNP. Lead Nurse Practitioner. . 5. th. most commonly diagnosed cancer in Australia. 8.9% of new cancer diagnoses. In 2009: . 10,193 cases (. 6034 . men, 4159 women). Projection to . 2020.  . 13,640. Mortality. In 2010 most common cause of cancer death. Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum. Friday, October 11, 2019. 6:15 PM – 7:45 PM . Chicago, Illinois. Faculty. . Moderator. Joel W Neal, MD, PhD. Nasser H Hanna, MD. Summary deck. 2. With over 7,000 medicines in development, the exciting new wave of medical innovation will play a key role in . addressing the challenges faced by patients and healthcare systems . Source: Health Advances analysis; Adis R&D Insight Database. March 2015, compiled by PhRMA.